UnitedHealth has raised concerns over the rollout of Medicare obesity drugs, highlighting several operational and structural challenges in the newly introduced Medicare pilot program aimed at expanding access to weight-loss treatments in the United States.
The company noted that there are still unresolved questions about how the program will function and whether major health insurers will fully participate.
The pilot program, known as “Balance,” is being developed under the US Centers for Medicare and Medicaid Services (CMS). It aims to standardize coverage terms and negotiate drug prices directly with manufacturers of GLP-1 medications, including treatments made by Eli Lilly and Novo Nordisk.
UnitedHealth executives said the current structure of the program presents “notable challenges.” They added that discussions with regulators are ongoing to address concerns before full implementation.
Insurers weigh participation decisions
The pilot program had set a deadline for insurers to opt in earlier this week. However, uncertainty remains over how many providers will join the initiative.
UnitedHealth confirmed it is reviewing participation in a related short-term demonstration program scheduled for July. This program will act as a bridge before the full rollout of the Medicare system for obesity treatment coverage.
Other major insurers, including CVS Health, have reportedly opted not to participate in the obesity coverage program, according to industry sources.
Analysts say insurers are cautious due to unclear pricing models, long-term financial risks, and regulatory uncertainty surrounding Medicare obesity drug coverage.
Policy and market impact
The initiative is part of broader US government efforts to reduce costs and expand access to weight-loss medications, which have seen rapidly increasing demand in recent years.
These drugs, known as GLP-1 therapies, are widely used for obesity management and diabetes treatment. However, their high cost has raised concerns among insurers and policymakers.
Following the news, shares of Eli Lilly and Novo Nordisk fell due to investor concerns over reimbursement uncertainty.
Ongoing negotiations with regulators
UnitedHealth stated that it remains in active discussions with CMS to refine the program’s structure. The company emphasized the importance of balancing affordability for patients with financial sustainability for insurers.
Officials say the goal is a standard pricing system to expand access to obesity treatment while controlling healthcare costs.
Despite challenges, the pilot is expected to move forward in phases, with adjustments based on insurer feedback. Its future depends on resolving concerns and setting long-term pricing.
